D. Fyfe

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.

D. Ferry, Adam J. de Smith, J Malkhandi et al. · PubMed · 1996 · 630 citations

Molecular Pharmacology, Medicinal Chemistry, Urology +14

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 597 citations · Full text

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Susan Dutton, David Ferry, Jane Blazeby et al. · The Lancet Oncology · 2014 · 329 citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +6

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

Anthony Maraveyas, Justin S. Waters, Rajarshi Roy et al. · European Journal of Cancer · 2011 · 314 citations · Full text

Pancreatic Cancer, Medicine, Gemcitabine Versus Gemcitabine +4

Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer

Russell Petty, Åsa Dahle-Smith, David A. Stevenson et al. · Journal of Clinical Oncology · 2017 · 137 citations · Full text

Tumor Biology, Radiation Oncology, Esophageal Cancer +15